Efficacy of the HLA-B

Aged Allergens / immunology Allopurinol / adverse effects Drug Hypersensitivity / diagnosis Febuxostat / therapeutic use Female Genotype HLA-B Antigens / genetics Histocompatibility Testing Humans Korea / epidemiology Male Mass Screening Middle Aged Prospective Studies Renal Insufficiency, Chronic / diagnosis Risk Skin / pathology

Allopurinol Chronic Drug hypersensitivity HLA-B(∗)58:01 allele Renal insufficiency

Journal

The journal of allergy and clinical immunology. In practice

ISSN: 2213-2201

Titre abrégé: J Allergy Clin Immunol Pract

Pays: United States

ID NLM: 101597220

Informations de publication

Date de publication:
04 2019

Historique:

received: 02 08 2018

revised: 03 12 2018

accepted: 04 12 2018

pubmed: 24 12 2018

medline: 1 8 2020

entrez: 24 12 2018

Statut: ppublish

Résumé

Thus far, human leukocyte antigen (HLA)-B To determine the usefulness of prospective screening for the HLA-B We prospectively enrolled 542 patients with chronic renal insufficiency (CRI) from 10 hospitals nationwide and performed DNA genotyping to determine whether they carried the HLA-B Nineteen patients in the prospective cohort developed mild and transient adverse reactions but none showed allopurinol-induced SCARs. By contrast, we identified 38 patients with allopurinol-induced SCARs (0.95%) in the historical control. The difference in the incidence of allopurinol-induced SCARs between the prospective cohort and historical control was statistically significant (0% vs 0.95%, respectively; P = .029). The present study demonstrated the clinical usefulness of the HLA-B

Sections du résumé

BACKGROUND

Thus far, human leukocyte antigen (HLA)-B

OBJECTIVE

To determine the usefulness of prospective screening for the HLA-B

METHODS

We prospectively enrolled 542 patients with chronic renal insufficiency (CRI) from 10 hospitals nationwide and performed DNA genotyping to determine whether they carried the HLA-B

RESULTS

Nineteen patients in the prospective cohort developed mild and transient adverse reactions but none showed allopurinol-induced SCARs. By contrast, we identified 38 patients with allopurinol-induced SCARs (0.95%) in the historical control. The difference in the incidence of allopurinol-induced SCARs between the prospective cohort and historical control was statistically significant (0% vs 0.95%, respectively; P = .029).

CONCLUSIONS

The present study demonstrated the clinical usefulness of the HLA-B

Identifiants

DOI: 10.1016/j.jaip.2018.12.012 PMID: 30580048

pubmed: 30580048

pii: S2213-2198(18)30834-1

doi: 10.1016/j.jaip.2018.12.012

pii:

doi:

Substances chimiques

Allergens 0

HLA-B Antigens 0

HLA-B*58:01 antigen 0

Febuxostat 101V0R1N2E

Allopurinol 63CZ7GJN5I

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

Pagination

1271-1276